Table 1 Adverse events

From: Erratum: Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study

  CMF ( n =173) UFT ( n =177)  
  Grade   Grade   
  Unknown 1 2 3 4 Incidence (%) Unknown 1 2 3 4 Incidence (%) P- value a
Leukopenia   87 50 6   82.7   49 10    33.3 P<0.001
Thrombocytopenia   21 2    13.3   35 2    20.9  
Haemoglobin   52 2 1   31.8   11 2    7.3 P<0.001
AST   45 11    32.4   45 16   1 35.0  
ALT   47 16    36.4   51 16 2   39.0  
Hepaplastin decrease   1     0.6   9     5.1 P<0.05
Total bilirubin   3     1.7   43 3 1   26.6 P<0.001
ALP   4     2.3   25     14.1 P<0.001
BUN   2 1    1.7   10     5.6  
Creatinine        1     0.6  
Anorexia   62 18 6   49.7 1 34 4 1   22.6 P<0.001
Nausea/vomiting   84 28 8   69.4 1 32 6 1   22.6 P<0.001
Diarrhoea 1 8     5.2 2 11     7.3  
Stomatitis   17 3    11.6   2 3    2.8 P=0.002
Pigmentation   7 2    5.2   12 4    9.0  
Numbness in fingers   1     0.6    1    0.6  
Alopecia   57 11    39.3   4     2.3 P<0.001
  1. Abbreviations: ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; CMF=cyclophosphamide–methotrexate–fluorouracil; UFT=uracil-tegafur.
  2. aχ2 test.